Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday, January 4th, BidAskClub reports.
Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. restated a “buy” rating and set a $75.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Piper Jaffray Companies reissued a “buy” rating and set a $70.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, December 18th. Raymond James cut Ultragenyx Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 2nd. ValuEngine cut Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, October 29th. Finally, Cowen reissued a “buy” rating and set a $59.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, December 18th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Ultragenyx Pharmaceutical currently has an average rating of “Buy” and an average target price of $73.50.
Shares of NASDAQ:RARE traded down $0.21 during midday trading on Friday, reaching $54.81. The company had a trading volume of 191,891 shares, compared to its average volume of 699,526. The company’s 50 day moving average price is $49.01 and its 200 day moving average price is $48.08. The company has a current ratio of 6.79, a quick ratio of 6.64 and a debt-to-equity ratio of 0.04. The stock has a market cap of $3.18 billion, a P/E ratio of -7.58 and a beta of 2.16. Ultragenyx Pharmaceutical has a 52-week low of $35.41 and a 52-week high of $74.50.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.71) by ($0.25). Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%. The company had revenue of $25.80 million during the quarter, compared to analysts’ expectations of $28.88 million. During the same period last year, the firm posted ($1.74) earnings per share. Ultragenyx Pharmaceutical’s quarterly revenue was up 119.4% compared to the same quarter last year. Research analysts forecast that Ultragenyx Pharmaceutical will post -7.24 EPS for the current fiscal year.
In other news, SVP Theodore Alan Huizenga sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $61.00, for a total transaction of $61,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.80% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC lifted its position in shares of Ultragenyx Pharmaceutical by 26.1% in the 3rd quarter. Squarepoint Ops LLC now owns 10,696 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 2,211 shares during the period. Millennium Management LLC purchased a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $248,000. California State Teachers Retirement System raised its stake in Ultragenyx Pharmaceutical by 1.2% during the 3rd quarter. California State Teachers Retirement System now owns 85,153 shares of the biopharmaceutical company’s stock valued at $3,643,000 after acquiring an additional 1,018 shares during the last quarter. Sector Gamma AS raised its stake in Ultragenyx Pharmaceutical by 117.2% during the 3rd quarter. Sector Gamma AS now owns 172,978 shares of the biopharmaceutical company’s stock valued at $7,400,000 after acquiring an additional 93,325 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $185,000.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
See Also: What is a resistance level?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
